Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
RESEARCH TOOLSreports
ELTP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.16 - $0.82
Previous CloseN/A
Volume475.03K
Average Volume (3M)2.17M
Market Cap
$626.12M
Enterprise Value$623.58M
Total Cash (Recent Filing)$11.32M
Total Debt (Recent Filing)$10.91M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,068,463,100
10 Day Avg. Volume2,043,203
30 Day Avg. Volume2,166,212
Financial Highlights & Ratios
PEG Ratio-1.91
Price to Book (P/B)11.66
Price to Sales (P/S)0.00
P/FCF Ratio126.55
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit15.56
Enterprise Value/Ebitda-303.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Elite Pharmaceuticals News
PremiumCompany Announcements
Elite Pharmaceuticals Reports Record Revenue Growth
PremiumCompany Announcements
Elite Pharmaceuticals Reports Strong Fiscal Year 2025 Results
PremiumCompany Announcements
Elite Pharmaceuticals Reports Strong Fiscal Year Performance
PremiumCompany Announcements
Elite Pharmaceuticals to Announce FY 2025 Results
PremiumCompany Announcements
Elite Pharmaceuticals Announces Positive Study Results
PremiumCompany Announcements
Elite Pharmaceuticals Launches Generic Percocet Version
PremiumCompany Announcements
Elite Pharmaceuticals Expands with New Northvale Facility
PremiumCompany Announcements
Elite Pharmaceuticals Reports Decline in Q3 2025 EarningsOptions Prices
Currently, No data available
---
Ownership Overview
20.74% Insiders
0.01% Other Institutional Investors
99.99% Public Companies and Individual Investors
ELTP FAQ
What was Elite Pharmaceuticals’s price range in the past 12 months?
Elite Pharmaceuticals lowest stock price was $0.16 and its highest was $0.82 in the past 12 months.
What is Elite Pharmaceuticals’s market cap?
Elite Pharmaceuticals’s market cap is $626.12M.
When is Elite Pharmaceuticals’s upcoming earnings report date?
Elite Pharmaceuticals’s upcoming earnings report date is Aug 18, 2025 which is in 38 days.
How were Elite Pharmaceuticals’s earnings last quarter?
Elite Pharmaceuticals released its earnings results on Jun 30, 2025. The company reported $0.016 earnings per share for the quarter, beating the consensus estimate of N/A by $0.016.
Is Elite Pharmaceuticals overvalued?
According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued.
Does Elite Pharmaceuticals pay dividends?
Elite Pharmaceuticals does not currently pay dividends.
What is Elite Pharmaceuticals’s EPS estimate?
Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elite Pharmaceuticals have?
Elite Pharmaceuticals has 1,068,463,100 shares outstanding.
What happened to Elite Pharmaceuticals’s price movement after its last earnings report?
Elite Pharmaceuticals reported an EPS of $0.016 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -8.219%.
Which hedge fund is a major shareholder of Elite Pharmaceuticals?
Among the largest hedge funds holding Elite Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Elite Pharmaceuticals’s shares valued at 0.
Elite Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELTP Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 82.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $114.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
222.59%
12-Months-Change
Fundamentals
Return on Equity
-7.77%
Trailing 12-Months
Asset Growth
15.22%
Trailing 12-Months
Company Description
Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. (ELTP) is a specialty pharmaceutical company engaged in the research, development, and production of niche generic and innovative oral drug products. The company operates primarily in the generic pharmaceuticals sector, focusing on developing a pipeline of product formulations that leverage its proprietary abuse-deterrent technology. Elite's core products include a range of immediate-release and controlled-release generic drugs, along with branded formulations, primarily targeting therapeutic areas such as pain management, infection, and hypertension.
ELTP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with record revenue growth and increased operating income. The successful launch of new products and a strengthening balance sheet were key highlights. However, noncash expenses affecting earnings per share and the competitive market for key products posed challenges.Read More>Technical Analysis
Oruka Therapeutics
―
Precigen
―
Relay Therapeutics
―
Opthea Limited Sponsored ADR
―
Mind Medicine
―